Of mice and men: lost in translation.
作者信息
Groisberg R, Maitra A, Subbiah V
机构信息
Department of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick.
Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Center.
出版信息
Ann Oncol. 2019 Apr 1;30(4):499-500. doi: 10.1093/annonc/mdz041.
Abstract
摘要
相似文献
1
Of mice and men: lost in translation.《人鼠之间》：迷失在翻译中。
Ann Oncol. 2019 Apr 1;30(4):499-500. doi: 10.1093/annonc/mdz041.
2
Preclinical rare cancer research to inform clinical trial design.开展临床前罕见癌症研究以指导临床试验设计。
Nat Rev Cancer. 2019 Sep;19(9):481-482. doi: 10.1038/s41568-019-0172-2.
3
Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets.针对中枢神经系统疾病的试验失败并不一定意味着临床前模型和药物靶点无效。
Nat Rev Drug Discov. 2016 Jul;15(7):516. doi: 10.1038/nrd.2016.88. Epub 2016 Jun 17.
4
Drug development: Raise standards for preclinical cancer research.药物研发：提高临床前癌症研究标准。
Nature. 2012 Mar 28;483(7391):531-3. doi: 10.1038/483531a.
5
Clinical trials are too often founded on poor quality pre-clinical research.
J Neurol. 2005 Sep;252(9):1115. doi: 10.1007/s00415-005-0803-2. Epub 2005 Mar 24.
6
Consider drug efficacy before first-in-human trials.在首次人体试验之前考虑药物疗效。
Nature. 2017 Jan 30;542(7639):25-27. doi: 10.1038/542025a.
7
Preclinical and clinical safety of monoclonal antibodies.单克隆抗体的临床前和临床安全性。
Drug Discov Today. 2007 Jul;12(13-14):540-7. doi: 10.1016/j.drudis.2007.05.010. Epub 2007 Jun 27.
8
The challenge of implementing high-throughput technologies in clinical trials.
Pharmacogenomics. 2005 Jun;6(4):435-8. doi: 10.1517/14622416.6.4.435.
9
Preclinical research: Make mouse studies work.临床前研究：让小鼠实验发挥作用。
Nature. 2014 Mar 27;507(7493):423-5. doi: 10.1038/507423a.
10
Above and Beyond Cancer Therapy: Translating Biomaterials into the Clinic.超越癌症治疗：将生物材料转化为临床应用。
Trends Cancer. 2020 Sep;6(9):730-732. doi: 10.1016/j.trecan.2020.04.008. Epub 2020 May 16.
引用本文的文献
1
Apigenin inhibits NLRP3 inflammasome activation in monocytes and macrophages independently of CD38.芹菜素可独立于CD38抑制单核细胞和巨噬细胞中NLRP3炎性小体的激活。
Front Immunol. 2025 Jan 7;15:1497984. doi: 10.3389/fimmu.2024.1497984. eCollection 2024.
2
Learning From Failure: Negative Trials in Oncology.从失败中学习：肿瘤学中的阴性试验
J Immunother Precis Oncol. 2023 Apr 12;6(2):59-60. doi: 10.36401/JIPO-23-X1. eCollection 2023 May.
3
N-of-1 Trials in Cancer Drug Development.癌症药物研发中的 N-of-1 试验
Cancer Discov. 2023 Jun 2;13(6):1301-1309. doi: 10.1158/2159-8290.CD-22-1377.
4
Of Mice, Not Men: When the Bench-to-Bedside Bridge Is Broken.《人鼠之间》：当从实验台到病床的桥梁断裂时。 （注：《人鼠之间》是美国作家约翰·斯坦贝克的小说，这里可能是借用其名来表达某种情境，具体含义需结合上下文确定）
J Immunother Precis Oncol. 2022 Oct 6;5(4):87-89. doi: 10.36401/JIPO-22-X3. eCollection 2022 Nov.
本文引用的文献
1
Time to publication of oncology trials and why some trials are never published.肿瘤学试验的发表时间以及部分试验未发表的原因。
PLoS One. 2017 Sep 21;12(9):e0184025. doi: 10.1371/journal.pone.0184025. eCollection 2017.
2
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies.晚期恶性肿瘤患者伊马替尼联合伊匹单抗的 I 期临床试验。
J Immunother Cancer. 2017 Apr 18;5:35. doi: 10.1186/s40425-017-0238-1. eCollection 2017.
3
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab.伊马替尼耐药的胃肠道间质瘤及其他晚期肉瘤患者联合使用KIT和CTLA-4阻断剂：达沙替尼加伊匹单抗的Ib期研究
Clin Cancer Res. 2017 Jun 15;23(12):2972-2980. doi: 10.1158/1078-0432.CCR-16-2349. Epub 2016 Dec 22.
4
Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting.评估提交至大型年度肿瘤学会议的临床试验摘要的最终发表情况。
Oncologist. 2016 Mar;21(3):261-8. doi: 10.1634/theoncologist.2015-0516. Epub 2016 Feb 17.
5
Drug development: Raise standards for preclinical cancer research.药物研发：提高临床前癌症研究标准。
Nature. 2012 Mar 28;483(7391):531-3. doi: 10.1038/483531a.
6
Believe it or not: how much can we rely on published data on potential drug targets?信不信由你：我们能在多大程度上依赖已发表的关于潜在药物靶点的数据？
Nat Rev Drug Discov. 2011 Aug 31;10(9):712. doi: 10.1038/nrd3439-c1.
7
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.伊马替尼通过抑制 IDO 增强胃肠道间质瘤中的抗肿瘤 T 细胞反应。
Nat Med. 2011 Aug 28;17(9):1094-100. doi: 10.1038/nm.2438.
8
Trial watch: phase III and submission failures: 2007-2010.试验观察：III期试验及提交失败情况：2007 - 2010年
Nat Rev Drug Discov. 2011 Feb;10(2):87. doi: 10.1038/nrd3375.
9
Commentary: practicing on the tip of an information iceberg? Evidence of underpublication of registered clinical trials in oncology.评论：在信息冰山一角上实践？肿瘤学领域注册临床试验发表不足的证据。
Oncologist. 2008 Sep;13(9):925-9. doi: 10.1634/theoncologist.2008-0133. Epub 2008 Sep 15.
10
Publication bias against negative results from clinical trials: three of the seven deadly sins.针对临床试验阴性结果的发表偏倚：七宗罪中的三宗。
Nat Clin Pract Neurol. 2007 Nov;3(11):590-1. doi: 10.1038/ncpneuro0618. Epub 2007 Sep 18.
Zotero 插件